Table 2.

Disease outcome and long-term side effects of the 75 PCNSL study patients

Variable	Patients
Treatment failure
Median (range) time to, y	0.77 (0.27-6.78)
Relapse*	12 (16)
Progression	2 (3)
Localization of failure, n
CNS only	8
CNS and other	2
Outside CNS only	2
Unknown	1
Multiple sites n.f.s.	1
Death	12 (16)
Relapse/progression, n	6
Without any therapy, n	1
Therapy-related toxicity, n	4
Unknown, n	1
Second malignancy, n	0
Continuous CR	58 (75)
Follow-up
Median (range), y	5.22 (0.19-25.29)
In CR1	53 (91)
In CR2	5 (9)
CR not yet achieved at LFU, n	5
Long-term side effects
Neurological	22 (29)
Endocrine	3 (4)
Cardiac	0 (0)
Other	7 (9)
Osteonecrosis, n	5
Psychosocial, n	1
GVHD, CMV-associated retinitis, n	1

Unless otherwise noted, data are shown as n (%).

CMV, cytomegalovirus; CR, complete remission; CR1, first complete remission; CR2, second complete remission; GVHD, graft-versus-host disease; LFU, last follow-up; n.f.s., not further specified.

^*ALCL, n = 6; DLBCL, n = 5; Burkitt lymphoma, n = 1; extranodal marginal zone lymphoma, n = 1; LBL, n = 1.